Concepedia
PubMed · 2009 · 33 citations · 12 references
Patients with high DYRK2 expression could be good candidates for chemotherapy.
12
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Patrick Therasse, Susan G. Arbuck, Elizabeth A. Eisenhauer et al. · JNCI Journal of the National Cancer Institute · 2000 · 15.7K citations
World Health Organization, Solid Tumors, Cancer Management +17
COMPARISON OF FOUR CHEMOTHERAPY REGIMENS FOR ADVANCED NON-SMALL-CELL LUNG CANCER
J Oan H. S Chiller, D Avid H Arrington, C Handra P. B Elani et al. · 2002 · 3.7K citations
Median Survival, Medicine, Cancer Management +13
DNA Repair by ERCC1 in Non–Small-Cell Lung Cancer and Cisplatin-Based Adjuvant Chemotherapy
Ken A. Olaussen, Ariane Dunant, Pierre Fouret et al. · New England Journal of Medicine · 2006 · 1.7K citations · Full text
Comparison of Survival and Quality of Life in Advanced Non–Small-Cell Lung Cancer Patients Treated With Two Dose Levels of Paclitaxel Combined With Cisplatin Versus Etoposide With Cisplatin: Results of an Eastern Cooperative Oncology Group Trial
Philip Bonomi, KyungMann Kim, Diane L. Fairclough et al. · Journal of Clinical Oncology · 2000 · 594 citations
Microtubule-associated protein tau: A marker of paclitaxel sensitivity in breast cancer
Roman Rouzier, Radhika Rajan, Peter J. Wagner et al. · Proceedings of the National Academy of Sciences · 2005 · 407 citations · Full text